CA2575204A1 - Methods of treating ophthalmic conditions - Google Patents

Methods of treating ophthalmic conditions Download PDF

Info

Publication number
CA2575204A1
CA2575204A1 CA002575204A CA2575204A CA2575204A1 CA 2575204 A1 CA2575204 A1 CA 2575204A1 CA 002575204 A CA002575204 A CA 002575204A CA 2575204 A CA2575204 A CA 2575204A CA 2575204 A1 CA2575204 A1 CA 2575204A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
individual
effective
ophthalmic condition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002575204A
Other languages
English (en)
French (fr)
Inventor
William A. Hare
Elizabeth Wolde Mussie
Larry A. Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan, Inc.
William A. Hare
Elizabeth Wolde Mussie
Larry A. Wheeler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc., William A. Hare, Elizabeth Wolde Mussie, Larry A. Wheeler filed Critical Allergan, Inc.
Publication of CA2575204A1 publication Critical patent/CA2575204A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002575204A 2004-07-26 2005-07-26 Methods of treating ophthalmic conditions Abandoned CA2575204A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59142304P 2004-07-26 2004-07-26
US60/591,423 2004-07-26
PCT/US2005/026703 WO2006015075A1 (en) 2004-07-26 2005-07-26 Methods of treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
CA2575204A1 true CA2575204A1 (en) 2006-02-09

Family

ID=35160080

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002575204A Abandoned CA2575204A1 (en) 2004-07-26 2005-07-26 Methods of treating ophthalmic conditions

Country Status (6)

Country Link
EP (1) EP1776097A1 (pt)
JP (1) JP2008507588A (pt)
AU (1) AU2005269293A1 (pt)
BR (1) BRPI0513862A (pt)
CA (1) CA2575204A1 (pt)
WO (1) WO2006015075A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
WO1997038691A1 (fr) * 1996-04-17 1997-10-23 Sumitomo Pharmaceuticals Co., Ltd. Medicament pour neuropathie retinienne
US20050009884A1 (en) * 1997-06-30 2005-01-13 Dreyer Evan B. Calcium blockers to treat proliferative retinal diseases
CA2295098A1 (en) * 1997-06-30 1999-01-07 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
AU9797598A (en) * 1997-11-14 1999-06-07 Alcon Laboratories, Inc. Treatment of diabetic retinopathy
EP1169061A1 (en) * 1999-03-12 2002-01-09 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US6761694B2 (en) * 2001-12-13 2004-07-13 Allergan, Inc. Methods for measuring retinal damage
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers

Also Published As

Publication number Publication date
WO2006015075A1 (en) 2006-02-09
JP2008507588A (ja) 2008-03-13
AU2005269293A1 (en) 2006-02-09
EP1776097A1 (en) 2007-04-25
BRPI0513862A (pt) 2008-05-20

Similar Documents

Publication Publication Date Title
US20220054435A1 (en) Nmda receptor antagonist formulation with reduced neurotoxicity
US20040213782A1 (en) Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
US11534396B2 (en) Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor
WO2009112878A1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
US11654140B2 (en) Treatment of ocular inflammatory diseases using laquinimod
CN101252952A (zh) 用于由泪液减少所引起的疾病的预防或治疗剂
TW201620883A (zh) １，２，４－二唑苯甲酸之鹽及醫藥組合物
Kim et al. Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia.
JP2009519962A (ja) 眼投与用局所メカミルアミン製剤およびその使用
KR20150032552A (ko) 치료 제제 및 치료 방법
KR20010040457A (ko) 안약 조성물
CA2575204A1 (en) Methods of treating ophthalmic conditions
CN115066232A (zh) 用于治疗眼病的组合物和方法
JP2007517885A (ja) 眼に投与するためのメマンチンおよびポリアニオン性ポリマーを含む組成物
US6534541B1 (en) Treatment of ocular disorders
RU2161982C1 (ru) Тетрапептид, стимулирующий функцию сетчатой оболочки глаза, фармакологическое средство на его основе и способ его применения
JP2022520832A (ja) 眼表面疼痛を治療する方法
WO1995000156A1 (en) Compositions and methods for treatment and prevention of retinal dysfunctions
US20240165089A1 (en) Method for treating myopia with vinpocetine
JP2024520206A (ja) 神経障害を調節する方法
US20150174122A1 (en) Methods for treating eye disorders using opioid receptor antagonists
MX2008008016A (en) Topical mecamylamine formulations for ocular administration and uses therof

Legal Events

Date Code Title Description
FZDE Dead